HK1065323A1 - Human dr4 antibodies and uses thereof - Google Patents

Human dr4 antibodies and uses thereof

Info

Publication number
HK1065323A1
HK1065323A1 HK04107906.4A HK04107906A HK1065323A1 HK 1065323 A1 HK1065323 A1 HK 1065323A1 HK 04107906 A HK04107906 A HK 04107906A HK 1065323 A1 HK1065323 A1 HK 1065323A1
Authority
HK
Hong Kong
Prior art keywords
antibodies
human
kits
diagnosis
articles
Prior art date
Application number
HK04107906.4A
Other languages
English (en)
Inventor
Anan Chuntharapai
Kyung Jin Kim
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HK1065323A1 publication Critical patent/HK1065323A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK04107906.4A 2001-07-03 2004-10-14 Human dr4 antibodies and uses thereof HK1065323A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30322001P 2001-07-03 2001-07-03
PCT/US2002/020712 WO2003066661A2 (fr) 2001-07-03 2002-06-29 Anticorps humains du dr4 et utilisations

Publications (1)

Publication Number Publication Date
HK1065323A1 true HK1065323A1 (en) 2005-02-18

Family

ID=27734188

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04107906.4A HK1065323A1 (en) 2001-07-03 2004-10-14 Human dr4 antibodies and uses thereof

Country Status (14)

Country Link
US (2) US7252994B2 (fr)
EP (2) EP1409544B1 (fr)
JP (1) JP4509570B2 (fr)
AT (1) ATE433996T1 (fr)
AU (2) AU2002366430B2 (fr)
CA (1) CA2451680C (fr)
CY (1) CY1110505T1 (fr)
DE (1) DE60232660D1 (fr)
DK (1) DK1409544T3 (fr)
ES (1) ES2328234T3 (fr)
HK (1) HK1065323A1 (fr)
IL (1) IL159527A0 (fr)
PT (1) PT1409544E (fr)
WO (1) WO2003066661A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7476383B2 (en) * 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
WO2003054216A2 (fr) * 2001-12-20 2003-07-03 Human Genome Sciences, Inc. Anticorps se liant de maniere immunospecifique a des recepteurs trail
ES2239886B1 (es) * 2003-11-05 2006-12-16 Universidad De Barcelona Metodo y aparato para la determinacion de la viabilidad celular.
AU2012200602B2 (en) * 2004-08-06 2012-11-08 Genentech, Inc. Assays and methods using biomarkers
ATE508205T1 (de) 2004-08-06 2011-05-15 Genentech Inc Tests und verfahren unter verwendung von biomarkern
KR101235479B1 (ko) 2004-08-06 2013-02-20 제넨테크, 인크. 바이오마커를 사용한 분석 및 방법
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
PT1915626E (pt) 2005-08-16 2012-02-03 Genentech Inc Sensibilidade da apoptose a apo2l/trail por ensaio de expressão de galnac-t14 em células/tecidos
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
WO2007046087A2 (fr) * 2005-10-16 2007-04-26 Yeda Research And Development Co.Ltd. Compositions pharmaceutiques et procedes de diagnostic de maladies, affections ou etats cutanes inflammatoires
WO2007061923A2 (fr) * 2005-11-18 2007-05-31 Takeda San Diego, Inc. Activateurs de la glucokinase
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
JP5386350B2 (ja) * 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
US9044457B2 (en) 2010-06-16 2015-06-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-DR4 agonist antibodies
EP3559049A4 (fr) 2011-10-28 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd Produits de recombinaison de polypeptide et utilisations de ceux-ci
EP2684896A1 (fr) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anticorps de la famille anti-DR5 ou bispécifique anticorps de la famille anti-DR5 multivalents et leurs procédés d'utilisation
MX370377B (es) 2013-04-29 2019-12-11 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos anti-cd38 y fusiones con interferón alfa-2b atenuado.
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
JP6730271B2 (ja) 2014-10-29 2020-07-29 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド インターフェロンα２Ｂバリアント
US10941204B2 (en) 2015-10-30 2021-03-09 Galaxy Biotech, Llc Highly potent antibodies binding to death receptor 4
CA3007033A1 (fr) 2015-12-01 2017-06-08 Genmab B.V. Anticorps anti-dr5 et procedes d'utilisation de ceux-ci

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8905669D0 (en) * 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
EP1132471A3 (fr) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag Protéines liant le TNF
WO1992015698A1 (fr) 1991-03-11 1992-09-17 Sheila Drover Anticorps monoclonaux murins reconnaissant des determinants polymorphes de l'antigene leucocytaire humain hla
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
WO1995021256A1 (fr) * 1994-02-04 1995-08-10 Bio Merieux Virus msrv1 et agent pathogene et/ou infectant msrv2 associes a la sclerose en plaques, leurs constituants nucleiques et leurs applications
ES2253753T3 (es) 1995-06-29 2006-06-01 Immunex Corporation Citocina que induce apoptosis.
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
KR20050004269A (ko) 1996-10-25 2005-01-12 휴먼 게놈 사이언시즈, 인코포레이티드 뉴트로킨 알파
AU713473B2 (en) 1996-12-23 1999-12-02 Immunex Corporation Receptor activator of NF-kappa B, receptor is member of TNF receptor superfamily
US6342363B1 (en) 1997-01-28 2002-01-29 Human Genome Sciences, Inc. Death domain containing receptor 4 nucleic acids and methods
US6433147B1 (en) * 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US20010010924A1 (en) 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
WO1998041629A2 (fr) 1997-03-17 1998-09-24 Human Genome Sciences, Inc. Recepteur 5 contenant un domaine de mort
RO128635A2 (ro) 1997-04-16 2013-07-30 Amgen Inc. Anticorp sau fragment al acestuia care se leagă la opgbp şi utilizarea acestuia, utilizarea unei forme solubile de odar, şi metodă de identificare a unui compus care descreşte activitatea opgbp
AU7126498A (en) 1997-04-16 1998-11-11 Millennium Pharmaceuticals, Inc. Tumor necrosis factor receptor related proteins tango-63d and tango-63e
EP1860187B1 (fr) 1997-05-15 2011-07-13 Genentech, Inc. Récepteur apo-2
AU8400398A (en) 1997-07-11 1999-02-08 Trustees Of The University Of Pennsylvania, The Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
WO1999004001A1 (fr) 1997-07-21 1999-01-28 Zymogenetics, Inc. Recepteur ztnfr-5 du facteur de necrose tumorale
CA2299619A1 (fr) 1997-08-06 1999-02-18 Regeneron Pharmaceuticals, Inc. Nouveau recepteur orphelin
EP1003864A1 (fr) 1997-08-15 2000-05-31 Idun Pharmaceuticals, Inc. Recepteurs de trail, acides nucleiques codant ces recepteurs et procedes d'utilisation
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
AU2093499A (en) 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
US20040180049A1 (en) * 1998-01-26 2004-09-16 Genentech, Inc. DR4 antibodies and uses thereof
ES2368823T3 (es) * 1998-01-26 2011-11-22 Genentech, Inc. Anticuerpos del receptor 4 de muerte (dr4) y usos de los mismos.
US20040120947A1 (en) * 1998-01-26 2004-06-24 Genentech, Inc. DR4 antibodies and uses thereof
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
ES2331901T3 (es) 1998-06-12 2010-01-19 Genentech, Inc. Anticuerpos monoclonales, anticuerpos que reaccionan de forma cruzada y procedimiento para la produccion de los mismos.
ATE429450T1 (de) * 1999-05-28 2009-05-15 Genentech Inc Chimärische dr4 antikörper und ihre verwendung
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US7279160B2 (en) * 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
CN100475848C (zh) * 2001-05-18 2009-04-08 麒麟麦酒株式会社 抗trail-r抗体
AU2002309647C1 (en) 2001-05-25 2008-09-11 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
ES2357225T3 (es) 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
WO2003038043A2 (fr) 2001-11-01 2003-05-08 Uab Research Foundation Combinaisons d'anticorps selectifs pour recepteur de ligand induisant l'apoptose liee au facteur de necrose tumorale et autres agents therapeutiques
WO2003042367A2 (fr) 2001-11-14 2003-05-22 Human Genome Sciences, Inc. Anticorps se liant specifiquement au niveau immunitaire a des recepteurs trail

Also Published As

Publication number Publication date
CA2451680A1 (fr) 2003-08-14
JP4509570B2 (ja) 2010-07-21
US7744881B2 (en) 2010-06-29
WO2003066661A3 (fr) 2003-11-27
AU2008260311A1 (en) 2009-01-15
DE60232660D1 (de) 2009-07-30
DK1409544T3 (da) 2009-10-26
ES2328234T3 (es) 2009-11-11
IL159527A0 (en) 2004-06-01
JP2005517021A (ja) 2005-06-09
US20080233646A1 (en) 2008-09-25
US20040147725A1 (en) 2004-07-29
AU2002366430A1 (en) 2003-09-02
ATE433996T1 (de) 2009-07-15
US7252994B2 (en) 2007-08-07
EP1409544B1 (fr) 2009-06-17
CY1110505T1 (el) 2015-04-29
AU2002366430B2 (en) 2008-09-18
CA2451680C (fr) 2011-04-19
EP1409544A2 (fr) 2004-04-21
WO2003066661A2 (fr) 2003-08-14
EP2192130A1 (fr) 2010-06-02
PT1409544E (pt) 2009-09-16
EP1409544A4 (fr) 2005-11-09

Similar Documents

Publication Publication Date Title
HK1065323A1 (en) Human dr4 antibodies and uses thereof
IL146448A0 (en) Dr4 antibodies and uses thereof
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
CY2020003I1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
WO2004011611A3 (fr) Anticorps anti-taci et utilisations de ceux-ci
IL127558A0 (en) Hepatocyte growth factor receptor agonists and uses thereof
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
MXPA02001911A (es) Anticuerpos ctla-4 humanos y sus usos.
GB0421639D0 (en) Methods and compositions relating to alzheimer's disease
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
IL216579A0 (en) Aminocyclohexyl ether derivatives and pharmaceutical compositions containing the same
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
EP2292666A3 (fr) Anticorps specifiques des neoplasmes et leurs utilisations
WO2004009029A3 (fr) Compositions et procedes de traitement et de prevention d'infections
WO2003044047A3 (fr) Genes de virulence, proteines, et leurs utilisations
NZ514691A (en) Method to type prion proteins
EP1370697A4 (fr) Medicaments a base de peroxyredoxine pour le traitement d'infections par le vih-1, et leurs methodes d'utilisation
AU2002316158A1 (en) Methods and compounds for the diagnosis of inflammatory disease and identification of pharmacological agents
WO2003027295A3 (fr) Procedes de diagnostic et de traitement de maladies associees a l'expression alteree de la jak1
EP1184465A3 (fr) Procédé pour le diagnostic des polymorphismes de MCT-1 humain et des agents associés avec ces polymorphismes
MY157231A (en) Aminocyclohexyl ether compounds and uses thereof
ZA200301143B (en) Biological materials and methods useful in the diagnosis and treatment of diseases.

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20220628